ATAT1

Across TCGA pan-cancer cohorts, ATAT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATAT1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATAT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATAT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where ATAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.270	0.499	.014	17	view →
UCEC	DFS	Median	II,III,IV	0.883	0.543	.037	8	view →
LSCC	OS	Quartile	All	0.908	0.650	.013	6	view →
LUAD	DFS	Tertile	All	0.831	0.600	.009	6	view →
HNSC	DFS	Tertile	All	1.000	0.930	.017	4	view →
CCRCC	DFS	Median	III,IV	0.862	0.569	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATAT1–PDAC (OS)

Open the PDAC breakdown →